NLRP1 and neoplasm: Recent studies showing that the serine dipeptidases DPP8/9 inhibit activation of NLRP1 has put renewed interest in past studies on inhibitors of these peptidases (like talabostat) as anti‐tumor agents (Eager et al., 2009).